Connect your AI

Insulet PODD Other comprehensive income/(loss) before reclassifications

Other comprehensive income/(loss) before reclassifications at other companies

West Pharmaceutical ServicesWST

——

Other financials

Income statement

Revenue$761.7M+33.9%

Gross profit$529.0M+29.3%

Operating income$122.1M+37.5%

Net income$91.1M+157%

EPS (diluted)$1.30+160%

Balance sheet

Cash & equivalents$480.4M-62.6%

Total debt$969.7M-45.5%

Total equity$1.3B-2.1%

Total assets$3.0B-15.1%

Cash flow

Operating cash flow$113.8M+78.4%

CapEx$24.3M+97.6%

Free cash flow$89.5M+73.8%

Valuation

Market cap$10.1B-19.9%

Enterprise value$10.59B-19.4%

P/E33.3×+2.0×

P/S3.5×-2.3×

Profitability

Gross margin71%+0.6pp

Operating margin17.5%+2.0pp

Net margin10.4%-7.9pp

FCF margin14.3%+1.1pp

Returns & leverage

Return on equity23%-14.9pp

Debt / equity0.7×-0.6×

Current ratio2.5×-2.0×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's other comprehensive income/(loss) before reclassifications.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Insulet's other comprehensive income/(loss) before reclassifications?: Insulet (PODD) reported other comprehensive income/(loss) before reclassifications of -$11.2M in Q1 2026.
How has Insulet's other comprehensive income/(loss) before reclassifications changed year-over-year?: Insulet's other comprehensive income/(loss) before reclassifications decreased by 722.2% year-over-year, from $1.8M to -$11.2M.